Recursion Pharmaceuticals

12/18/2025

🎉 Recursion’s Chief Platform Officer Lina Nilsson was recently chosen for the AI Women Power List by AI Utah and the Women Tech Council. 🎉

The award recognizes women who have demonstrated leadership in advancing AI and are setting an example for innovators across the state.

Lina joined Recursion in 2018 and became the company’s first Chief Platform Officer in May 2025.

She has championed an AI-first approach to end-to-end drug discovery and ensures that we are pushing the boundaries of what the Recursion OS can do with continued investment in AI, ML, and automation, and in translating those advances into real impact for patients.

🙌 Congrats to Lina on this well-deserved recognition!

12/17/2025

🔹 AI drug discovery, validated.

Recursion recently announced the first clinical validation of its AI-enabled drug discovery platform – positive Phase 1b/2 data for the ongoing TUPELO study evaluating its AI-identified drug, REC-4881, in Familial Adenomatous Polyposis (FAP).

This progressive rare disease affects more than 50,000 people in the U.S. and EU and has no FDA-approved treatments. It results in hundreds to thousands of polyps developing in the colon, and requires a lifetime of invasive surveillance and surgery.

Recursion used AI not only to deliver the first potential treatment for this disease but also to quantify – for the first time at scale – the true natural progression of polyp burden in the trial-relevant population.

It demonstrates the incredible breakthroughs that can come from merging proprietary data and AI – and the tangible impact on patient lives.

👉 See the full study results here: https://ir.recursion.com/news-releases/news-release-details/positive-phase-1b2-results-ongoing-rec-4881-tupelo-trial-0

12/16/2025

How is real-world data transforming healthcare and medicine?

In the latest episode of our podcast, TechBio Talks, host Najat Khan, PhD, talks to Amy Abernethy, MD, PhD, cofounder of Highlander Health.

Amy is a physician, innovator, and executive who has pioneered oncology real-world evidence generation to address gaps in patient care and access.

They talk about the three “waves” of real-world data leading to today’s multimodal data; how that real-world data ties into patients’ longitudinal health story; and the difference between real-world data and real-world evidence. And they dive into how this data is driving major innovative shifts to improve clinical trials and drug discovery.

🎙️Listen and follow on:

➡️ Spotify: https://
open.spotify.com/episode/5alrWa
eoXJ0Sqni56UAPV1

➡️ YouTube: https://
youtube.com/watch?v=2JZoJR
LLZZk

➡️ Apple: https://
podcasts.apple.com/us/podcast/tec
hbio-talks-episode-4-highlander-healths-amy-abernethy/id1834770803?i=1000741516803

12/10/2025

Earlier this week, Beth Bruckheimer, PhD, VP of Clinical Development, shared details on our positive Phase 1b/2 results from the ongoing TUPELO study of REC-4881 for Familial Adenomatous Polyposis (FAP). This data offers new hope for patients living with this relentlessly progressive disease, which currently has no approved pharmacotherapies.

As Beth shared, this data underscores the potential for REC-4881 to be a first-in-disease and best-in-class precision medicine to address the underlying biology of FAP.

👉 Watch Beth’s section of the webinar here: https://www.youtube.com/watch?v=mv0cOtYawqs

In this video, Beth Bruckheimer, PhD, VP of Clinical Development at Recursion, shared details on our positive Phase 1b/2 results from the ongoing TUPELO stud...

12/08/2025

Today we announced positive Phase 2 results from our ongoing TUPELO trial evaluating REC-4881 in patients with familial adenomatous polyposis (FAP) – a rare, inherited disease with no approved pharmacologic treatments.

Treatment with REC-4881 demonstrated rapid and durable reductions in polyp burden in the study, with a median 43% reduction in total polyp burden (n=12) after 12 weeks of treatment. 82% of evaluable patients (9 of 11) maintained reductions at Week 25—12 weeks after stopping therapy—with a 53% median decrease from baseline.

REC-4881 has a safety profile consistent with MEK1/2 inhibition, with the majority of treatment-related adverse events (TRAEs) being Grade 1 or 2, and Grade 3 events occurring in 15.8% of the safety-evaluable patients (n=19) and no Grade ≥4 TRAEs reported to date.

These data signal the possibility for a disease modifying, non-surgical option for patients living with this disease, which leads to the growth of hundreds to thousands of gastrointestinal polyps and has a nearly 100% risk of developing into colorectal cancer if left untreated.

We look forward to engaging with regulators in 2026 to discuss a registration pathway.

🔹 Learn more at our webinar today at 8:00 am ET / 6:00 am MT / 1:00 pm GMT.

▪️ YouTube: https://www.youtube.com/

▪️ X: https://x.com/RecursionPharma

▪️ LinkedIn : https://www.linkedin.com/company/recursion-pharmaceuticals

👉 Read the press release: https://ir.recursion.com/news-releases/news-release-details/positive-phase-1b2-results-ongoing-rec-4881-tupelo-trial-0

12/04/2025

🚀 Recursion has been laying the foundation for a virtual cell from day one – including massive-scale, proprietary biological and chemical datasets, AI models, and one of the industry’s most powerful supercomputers.

💥 In a new video and article we share our progress – and where we’re headed next:

▪️ It started with creating a proprietary data moat, generating and aggregating more than 65 petabytes of multimodal and fit-for-purpose data.

▪️ Then we built a system of interconnected AI models capable of processing and analyzing all of that data at massive scale.

▪️ These AI models power our end-to-end drug discovery and development engine, helping us identify novel biological targets, precision design chemical compounds, and design and run clinical trials in the most effective way possible.

As Daniel Cohen, President of Valence Labs, Recursion’s AI research engine, says, this is the path we are charting toward a virtual cell: computational systems that can accurately simulate cellular and patient-level responses to therapeutic interventions.

This allows us to flip the script on traditional drug discovery. The virtual cell, not the lab, becomes the starting place for new hypotheses, and the lab becomes the tool to validate those predictions.

👉 Read the article here: https://www.recursion.com/news/since-its-inception-recursion-has-been-building-the-foundation-for-the-first-virtual-cell

12/04/2025

🚀 Recursion has been laying the foundation for a virtual cell from day one – including massive-scale, proprietary biological and chemical datasets, AI models, and one of the industry’s most powerful supercomputers.

💥 In a new video and article we share our progress – and where we’re headed next:

▪️ It started with creating a proprietary data moat, generating and aggregating more than 65 petabytes of multimodal and fit-for-purpose data.

▪️ Then we built a system of interconnected AI models capable of processing and analyzing all of that data at massive scale.

▪️ These AI models power our end-to-end drug discovery and development engine, helping us identify novel biological targets, precision design chemical compounds, and design and run clinical trials in the most effective way possible.

As Dan Cohen, President of Valence Labs, Recursion’s AI research engine, says, this is the path we are charting toward a virtual cell: computational systems that can accurately simulate cellular and patient-level responses to therapeutic interventions.

This allows us to flip the script on traditional drug discovery. The virtual cell, not the lab, becomes the starting place for new hypotheses, and the lab becomes the tool to validate those predictions.

👉 Read the article here: https://www.recursion.com/news/since-its-inception-recursion-has-been-building-the-foundation-for-the-first-virtual-cell

12/02/2025

The advantages of a hybrid computing approach.

Recently, CTO Ben Mabey spoke with Matt Marshall at a VentureBeat AI Impact Series event about the advantages of a hybrid on-prem / cloud approach to computing in order to generate massive datasets, train AI models, and scale operations with the greatest speed and flexibility.

Recursion was vindicated early-on in its decision to invest in a supercomputer, Ben shared. We had petabytes of cell data and were training models using transformers that required massive computing power that simply wasn’t available from cloud providers at the time. “It felt really good to have a cluster of our own on hand that we could turn to,” Ben said. That on-site supercomputer also means people feel empowered to innovate, he added, and offers a clear cost advantage.

But as Ben shared, cloud compute is critical for on-demand scaling tasks – including running inferences from our phenomics data and our benchmarking workloads around the release of models like OpenPhenom.

“If it’s a large training job we put it on prem, but if it’s one of these shorter workloads we put it in the cloud,” Ben said.

That combination allows us to maximize speed and flexibility on the path to new breakthroughs.

https://www.youtube.com/watch?v=DawSPPxi1TE

The On-Prem Power Play: Ben Mabey, CTO of Recursion, helped build one of pharma’s largest supercomputers. His team bet on GPUs when everyone else went all-in...

12/01/2025

🔹 New data readout coming.

Join us for a webinar on Dec. 8, 8:00 am ET / 6:00 am MT / 1:00 pm GMT where we’ll share updated clinical data from our ongoing TUPELO Phase 1b/2 trial of REC-4881 in Familial Adenomatous Polyposis (FAP).

REC-4881 is a potentially first-in-disease small molecule MEK 1/2 inhibitor that was identified using Recursion’s AI platform.

✨ Presenters include:
▪️ Najat Khan, PhD, Chief R&D Officer and Chief Commercial Officer and incoming CEO and President, Recursion
▪️ David Mauro, M.D., Ph.D., Chief Medical Officer, Recursion
▪️ Elizabeth Bruckheimer, Ph.D., Ph.D., Vice President of Clinical Development, Recursion
▪️ Jessica Stout, D.O., Assistant Clinical Professor, University of Utah School of Medicine
▪️ Alfred M. Cohen, MD, FACS, FASCRS, Former CMO, Cancer Prevention Pharmaceuticals; Prior Chief, Colorectal Service, Memorial Sloan Kettering Cancer Center

✨ The webinar will be streamed live on
▪️ YouTube: https://www.youtube.com/
▪️ LinkedIn: https://www.linkedin.com/company/recursion-pharmaceuticals/
▪️ X: https://x.com/RecursionPharma

👉 More: https://ir.recursion.com/news-releases/news-release-details/recursion-announces-webinar-upcoming-clinical-data-readout

11/26/2025

🚀 Want to work on the cutting edge of AI drug discovery?

We’re looking for an Associate Principal of TechBio Discovery Biology in our Salt Lake City or New York City office.

✨ About the role:

▪️ You’ll be working at the intersection of technology and biology, and play a critical role in defining and executing our oncology strategy, integrating traditional drug discovery principles with cutting-edge computational approaches.

▪️ You’ll lead scientific initiatives focused on successfully delivering various small molecule programs from initial hit to candidate selection and IND submission.

▪️ You’ll contribute to novel target insight generation, patient refinement, and patient selection strategies within several early discovery programs, with the opportunity to improve the Recursion OS itself.

👉 Learn more and apply: https://job-boards.greenhouse.io/recursionpharmaceuticals/jobs/7305184?gh_src=2uzvfbmw1us

11/25/2025

In a new story in STAT, incoming CEO and President Najat Khan, PhD spoke to Andrew Joseph about why she’s confident in building on the company’s progress in Recursion’s next chapter.

On why she’s excited to lead.
“Pairing ambition with discipline is very important. As you scale a company, you can’t do everything. For me, what I’ve always done is impact for patients, and shareholder value.”

On the importance of culture.
“Some people understand AI really well, but they underestimate the complexity of biology and chemistry. Others understand biology and chemistry. But finding people that can speak both languages — I use the word bilingual — is one of the hardest things. That is a culture we have at Recursion.“

About how she’s continuing to position Recursion to win.
“This space is moving incredibly fast. Every day, there’s a new model, new data. We need to keep investing in our platform, but only in areas where we can win. We also have to be disciplined. I think the fact that we reduced operating costs by 35% shows you the kind of discipline that we will continue to have. Every dollar counts. So you’ll see rapid go, no-go decisions. We’re not like a biotech with one or two assets. We have more coming. It’s a portfolio view — what do I think has the best chance?”

Read more: https://www.statnews.com/2025/11/21/recursion-ai-drug-development-najat-khan/

11/24/2025

🚀 The energy and momentum happening around life sciences in London – fueled by innovation and investment in AI – is undeniable.

That momentum was on full display last week at the Jefferies Global Healthcare Conference and London Life Sciences Week presentations and events.

💥 Some highlights:

▪️ Recursion CFO Ben Taylor spoke on the panel: “AI in Life Sciences: Is It All Hype?” where he shared that what gives him hope is how AI is enabling better decision-making. “We have more data. We’re not basing tens of millions of dollars and years of time and patients’ lives off of a couple dozen mice, how they behave, how they react. There is this power that comes out of the data and the analytics that’s informing our decision-making and that really gives me hope.” We’re not just designing drugs, Ben told the audience, we’re creating treatments for specific patient populations, guided by data.

▪️ We also had a great time at the invite-only BACKED VC event, where moderator Yasmin Siraj spoke with Jon Symonds, chair of GSK and Chris Gibson about their personal journeys and lessons learned in discovering, developing and scaling category-defining therapeutics.

▪️ And incoming Recursion CEO and President Najat Khan, PhD spoke at Jefferies about Recursion’s next era and what differentiates us. “We have over 65 petabytes of proprietary data. Every day you see different models being developed,” she said, “but they’re usually trained on the same public data sets…Differentiation comes from having proprietary, high-quality data. We run a couple of million experiments a week. For a 600-person company to have that much data that’s been generated and supporting multiple programs wholly owned and with partnerships, it’s difficult to do unless you also automate and have a wet-lab and dry-lab loop where your models get good enough that it actually predicts which experiments you should do. That’s where the world for discovery and development is going.”

Can’t wait to continue our London conversations and keep the momentum going!